<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Zai Lab Ltd ( (HK:9688) ) has shared an announcement. Zai Lab reported first-quarter 2026 revenues of $99.6 million, reflecting expected seasonal dynamics and competitive pressure on key drugs ZEJULA and VYVGART, while underscoring that its commercially profitable regional business continues to provide a stable base. Management highlighted preparations for the China launch of KarXT for schizophrenia in the second quarter and ongoing regulatory review of TIVDAK, alongside positive Phase 3 data for povetacicept in IgA nephropathy and elegrobart in thyroid eye disease as key drivers of future regional growth. The company emphasized strong momentum in its global R&amp;D pipeline, with standout clinical data for its oncology asset zoci in small cell lung cancer and extrapulmonary neuroendocrine carcinomas and rapid enrollment in the registrational DLLEVATE trial, as well as new collaborations with Amgen and Boehringer Ingelheim that could position zoci as a backbone therapy in neuroendocrine tumors. In immunology, ZL-1503 showed promising preclinical dual-pathway activity across atopic diseases, supporting a Phase 1/1b study now underway, reinforcing Zai Lab’s strategy to scale its research engine and enhance its competitive positioning in both oncology and immunology. The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page. More about Zai Lab Ltd Zai Lab Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, immunology and other serious diseases, with operations spanning China and global markets. Its portfolio includes marketed products such as ZEJULA and VYVGART in its regional business, alongside a growing global pipeline that features assets like zocilurtatug pelitecan (zoci), ZL-1503 and upcoming launches including KarXT and potential approvals for TIVDAK, povetacicept and elegrobart. Average Trading Volume: 10,778,890 Technical Sentiment Signal: Sell Current Market Cap: HK$18.31B </div>

ZLAB

09688

520690

Zai Lab Ltd (HK:9688) reported Q1 2026 revenues of $99.6 million, impacted by seasonal dynamics and competition for ZEJULA and VYVGART. The company is preparing for the China launch of KarXT for schizophrenia and is undergoing regulatory review for TIVDAK. Positive Phase 3 data for povetacicept and elegrobart were highlighted, along with strong momentum in its R&D pipeline, particularly for zoci in oncology. The latest analyst rating is a Hold with a price target of HK$18.00. Zai Lab focuses on innovative therapies in oncology and immunology, with a market cap of HK$18.31B.

- Zai Lab Ltd reported first-quarter 2026 revenues of $99.6 million, impacted by seasonal dynamics and competition for key drugs.  
- The company is preparing for the China launch of KarXT for schizophrenia and has positive data for its ongoing projects, positioning itself for regional growth.  
- Zai Lab’s strong R&D pipeline includes promising developments in oncology and immunology, maintaining a market cap of HK$18.31 billion with a current analyst rating of Hold at a HK$18.00 price target.

Tip Ranks

Zai Lab

ZAI LAB

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

Huaan Hang Seng Biotech ETF

ICBCCS SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI 300 Health Care ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

China Universal 800 Health Care ETF

Amgen

Zai Lab Q1 2026 Results Highlight Pipeline Momentum and Upcoming China Launches